Eli Lilly & Co. is buying three clinical-stage vaccine developers for as much as $3.8 billion, leveraging its obesity-fueled ...

By Sriparna Roy May 26 (Reuters) - Eli Lilly said on Tuesday it will buy three vaccine developers in deals worth up to $3.8 ...

Via the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus.

The deals give Lilly vaccines targeting shingles, bacterial pathogens, and Epstein-Barr virus as it expands beyond weight ...

The drugmaker said it would spend up to $4 billion to acquire small companies exploring vaccines for shingles, Epstein-Barr ...

Eli Lilly has agreed to acquire three privately-held developers of vaccines for infectious diseases for a combined up-to-$3.83 billion cash, in deals intended to expand the acquisitive pharma giant’s ...

On May 26, Reuters reported that Eli Lilly and Company (NYSE:LLY) plans to acquire three vaccine developers in deals worth up ...

Eli Lilly (LLY) stock is in focus as the company agrees to buy three vaccine developers in deals worth up to $4B in total. Read more here.

Eli Lilly and Company is pivoting significantly toward infectious disease prevention by executing agreements to buy three ...